同质抗体-药物结合物的分支连接器:多长时间足够长?
Evgeny L Gulyak1, Olga A Komarova1,2, Yury A Prokopenko1
1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Miklukho-Maklaya 16/10, 117997 Moscow, Russia.
International journal of molecular sciences
|January 8, 2025
概括
在同质抗体-药物联合体 (ADCs) 中,分支链接体的长度对其细胞毒性活性产生重大影响. 较长的链接器增强功效,而较短的链接器可能会由于影响药物释放的硬质障碍而降低功效.
科学领域:
- 生物结合化学 生物结合化学
- 抗体与药物联合体 (ADCs) 是一种抗体与药物联合体.
- 蛋白质工程是指蛋白质工程.
背景情况:
- 同质的抗体-药物联合体 (ADC) 提供了优越的药理学特征,而不是异质的ADC.
- 酶结合,例如使用微生物转胺酶 (MTGase),可以实现特定站点的有效载荷附着,以实现同质性.
- 在同质的ADC中实现更高的药物对抗体比率 (DAR) 需要分支链接剂,但它们的结构影响尚不清楚.
研究的目的:
- 研究分支链子结构与同质ADCs的特性之间的关系.
- 合成和评估基于trastuzumab的同质ADCs,具有不同的分支链路长度和药物对抗体比 (DARs).
主要方法:
- 合成两种不同长度的分支氨基三化连接器 (包含PEG4片段).
- 通过酶结合 (MTGase) 和与单甲基奥里斯塔丁E (MMAE) 的生物正对应合,制备均的trastuzumab-ADCs (DAR 6,"短"和"长"链接器).
- 对照ADC的表征:异质的DAR 6和同质的DAR 2的 trastuzumab-MMAE合物.
主要成果:
- 这四种Trastuzumab-MMAE结合物都表现出与HER2相似的结合亲和力.
- 细胞毒性有显著的变化:"长"同质DAR 6ADC与异质DAR 6对照的强度相匹配.
- "短"同质的DAR 6ADC显示出显著降低的功效,效果不如DAR 2结合物.
结论:
- 分支链子长度是ADC细胞毒性活性的关键决定因素.
- 通过较短的分支链接器引入的固体阻碍可能会阻碍溶酶酶裂变,减少药物释放和效力.
- 酶结合提供了一个可行的途径,用于创建基于链接器设计的可调节性质的同质ADC.
关键词:
在MMAE中,MMAE是最重要的.气体 MTG 气体 MTG 气体抗体 药物联合体 抗体 药物联合体分支链接器 分支链接器可以切割的链接器.酶性修饰是一种酶性修饰.同质的结合物是同质的结合物.更多相关视频
08:47Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
9.4K
13:53Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
4.9K
相关概念视频
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Phase II Conjugation Reactions: Overview
156
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
156
Antibody Structure
58.9K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
58.9K
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Ligand Binding Sites
12.7K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.7K
Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
